Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Biocon talks about evolving payer dynamics for Humira biosimilar • Source: Shutterstock

Biocon, Ltd.’s early commentary on the way things are shaping in the US Humira biosimilar market reflected what some other key players have been saying – uptake hasn’t been rapid and the payer landscape is still developing.

At the earnings call for the fiscal first quarter, Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics Ltd (BBL), referred to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip